Cite
HARVARD Citation
Cudkowicz, M. et al. (2021). Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet neurology. 20 (10), pp. 821-831. [Online].